The sensitive detection and quantitation of antibody to HCV by using a microsphere-based immunoassay and flow cytometry

Cytometry

Volumn 29, Issue 2, 1997, Pages 106-112

  McHugh, Thomas M ^a   Viele, Maurene K ^a   Chase, Eric S ^b   Recktenwald, Diether J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cytek Development   (United States)

^c AmCell Corporation   (United States)

Author keywords

Flow cytometry; Hepatitis C antibodies; Hepatitis C viruses; Immunoassay; Immunologic techniques; Microspheres; Serodiagnosis

Indexed keywords

HEPATITIS C ANTIBODY;

ANTIBODY DETECTION; ARTICLE; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS DETECTION;

BLOOD DONORS; FLOW CYTOMETRY; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOASSAY; IMMUNOENZYME TECHNIQUES; MICROSPHERES; RNA HELICASES; SENSITIVITY AND SPECIFICITY; SERINE ENDOPEPTIDASES; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0030754944     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19971001)29:2<106::AID-CYTO2>3.0.CO;2-B     Document Type: Article

References (20)

1. American Association of Blood Banks. FDA notification requirement: ALT procedure Change; Changes to the Circular of Information. Association Bulletin 95-7 AABB, Bethesda, MD, 1995.
2. Alter MJ: Review of serologic testing for hepatitis C virus infection and risk of posttransfusion hepatitis C. Arch Pathol Lab Med 118:342-345, 1994.
3. Bresters D, Zaaijer HL, Cuypers HTM, Reesink HW, Winkel IN, van Excel-Oehlers PJ, van Drimmelen AAJ, Jansen PLM, van der Poel CL, Lelie PN: Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients. Transfusion 33:634-638, 1993.
4. Courouce AM, Bouchardeau F, Giralt A, Le Marrec N: Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 343:853-854, 1994.
5. Donahue JG, Munoz A, Ness P, Brown DE, Yawn DH, McAllister HA, Reitz BA, Nelson KE: The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 327:369-373, 1992.
6. Farci P, Alter HJ, Govindarajan S, Wong, DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, Purcell RH: Lack of protective immunity against reinfection with Hepatitis C Virus. Science 258:135-140, 1992.
7. Gruber A, Norder H, Magnius L, Rotzen M, Rubio C, Grillner L, Bjorkholm M: Later seroconversion and high chronicity rate of hepatitis C virus infection in patients with hematologic disorders. Ann Oncol 4:229-234, 1993.
8. Lesniewski R, Okasinski G, Carrick R, Van Scant C, Desai S, Johnson R, Scheffel J, Moore B, Mushawar I: Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: A new marker of HCV infection closely associated with viremia. J Med Virol 45:415-422, 1995.
9. Marcellin P, Martinot-Peignoux M, Elias A, Branger M, Courtois F, Level R, Erlinger S, Benhamou JP: Hepatitis C virus (HCV) viremia in human immunudeficiency virus-seronegative and seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 170:433-435, 1994.
10. McHugh TM: Flow microsphere immunoassay for the quantitative and simultaneous detection of multiple soluble analytes. In: Methods Cell Biology Second Edition, Darzynkiewicz Z, Robinson JP, Crissman HA (eds.). Vol 42, 33:575-595, Academic Press, New York, 1994.
11. Morsica G, Panese S, Novati R, Migone TS, Barin P, Mustara D, Frigato A, Lazzarin A: Hepatitis C virus infection in blood donors with indeterminate results in second-generation recombinant immunoblot assay. Transfusion 34:555-556, 1994.
12. NIH Consensus Statement. Infectious Disease Testing for Blood Transfusions 13:1-27, National Institutes of Health, Bethesda, MD, 1995.
13. Pawlotsky JM, Fleury A, Choukroun V, Deforges L, Roudot-Thoraval F, Aumont P, Duval I, Dhumeaux D: Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA. J Clin Microbiol 32:1357-1359, 1994.
14. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. N Engl J Med 334:1685-1690, 1996.
15. Shakil AO, Conry-Cantilena C, Alter H, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, Bisceglie AM: Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic, and histologic features. The hepatitis C Study Group. Ann Intern Med 123:330-337, 1995.
16. Tobler LH, Busch MP, Wilber J, Dinello R, Quan S, Polito A, Kochesky R, Bahl C, Nelles M, Lee SR: Evaluation of indeterminate c22-3 reactivity in volunteer blood donors. Transfusion 34:130-134, 1994.
17. Vallari DS, Jett BW, Alter HJ, Mimms LT, Holzman R, Shih J W-K: Serologic markers of posttransfusion hepatitis C viral infection. J Clin Microbiol 30:552-556, 1992.
18. Wuamans L, Claeys H, Verhaert H, Mertens W, Vermylen C: Hepatitis C virus confirmation in blood donor screening. Vox Sang 64: 145-149, 1993.
19. Zaaijer HL, Vrielink H, van Excel-Oehlers PJ, Cuypers HT, Lelie PN: Confirmation of hepatitis C infection: A comparison of five immunoblot assays. Transfusion 34:603-607, 1994.
20. Zanella A, Conte D, Prati D, Mozzi F, Capelli C, Zanuso F, Fraquelli M, Bosoni P, Vianello L, Pappalettera M, Velio P, Montagnolo G, Bianchi PA, Sirchia G: Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay. Hepatology 21:913-917, 1995.